GUIA%20SEGUNDAFINAL

Programa de Equivalentes Terapéuticos
Comisión de Farmacia y Terapéutica de la provincia de Granada
L04. INMUNOSUPRESORES
En guía: Ig Antitimocítica (conejo), certolizumab pegol iny, ácido micofenólico
oral, golimumab iny, sirolimus oral, anakinra iny, leflunomida oral, ustekinumab
iny, everolimus oral, tocilizumab iny, natalizumab iny, ciclosporina iny,
abatacept iny, ciclosporina oral, fingolimod oral, tacrolimus iny, etanercept iny,
tacrolimus oral, infliximab iny, azatioprina oral, adalimumab iny, talidomida,
lenalidomida oral.
Biblografía
1. Complejo Hospitalario Universitario de Albacete. Programa de equivalentes
terapéuticos. 2006.
2. Jun Kawakami, MD, FRCSC and Alvaro Morales, MD, FRCSC, OC; Can Urol
Assoc J. 2013 Mar-Apr; 7(3-4): E226–E230. Published online Apr 16, 2013.
3. Novara G1, Galfano A, Secco S, Ficarra V, Artibani W., Urol Int.
2009;82(3):249-55.
4. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson
AL, et al. A controlled trial of bicalutamide versus flutamide, each in
combination with luteinizing hormone-releasing hormone analogue therapy,
in patients with advanced prostate carcinoma. Analysis of time to
progression. CASODEX Combination Study Group. Cancer. 1996
;78(10):2164–9.
5. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase
II neoadjuvant comparison between letrozole, anastrozole, and exemestane
for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast
cancer: clinical and biomarker outcomes and predictive value of the baseline
PAM50-based int. J Clin Oncol. 2011;29(17):2342–9.
6. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al.
Exemestane versus anastrozole in postmenopausal women with early
breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J
Clin Oncol. 2013;31(11):1398–404.
7. Welte K. Expert Opin Biol Ther. 2014 Jul;14(7):983-93.
8. Gardellini A et al. Ecancermedicalscience. 2013 Jun 25;7:327.
83